| Literature DB >> 31720721 |
N A Goto1,2, A C G Weststrate3, F M Oosterlaan4, M C Verhaar5, H C Willems6, M H Emmelot-Vonk4, M E Hamaker7.
Abstract
Patients with chronic kidney disease (CKD) are more likely to experience falls and fractures due to renal osteodystrophy and the high prevalence of risk factors for falls. However, it is not well established how great the risk is for falls and fractures for the different stages of CKD compared to the general population. The objective of this systematic review and meta-analysis was to assess whether, and in which degree, CKD was associated with falls and fractures in adults. A systematic search in PubMed, Embase, CINAHL, and The Cochrane Library was performed on 7 September 2018. All retrospective, cross-sectional, and longitudinal studies of adults (18 years of older) that studied the association between CKD, fractures, and falls were included. Additional studies were identified by cross-referencing. A total of 39 publications were included, of which two publications assessed three types of outcome and four publications assessed two types of outcome. Ten studies focused on accidental falling; seventeen studies focused on hip, femur, and pelvis fractures; seven studies focused on vertebral fractures; and thirteen studies focused on any type of fracture without further specification. Generally, the risk of fractures increased when kidney function worsened, with the highest risks in the patients with stage 5 CKD or dialysis. This effect was most pronounced for hip fractures and any type of fractures. Furthermore, results on the association between CKD and accidental falling were contradictory. Compared to the general population, fractures are highly prevalent in patients with CKD. Besides more awareness of timely fracture risk assessment, there also should be more focus on fall prevention.Entities:
Keywords: Accidental falls; Chronic kidney disease; Dialysis; Fracture
Mesh:
Year: 2019 PMID: 31720721 PMCID: PMC6946749 DOI: 10.1007/s00198-019-05190-5
Source DB: PubMed Journal: Osteoporos Int ISSN: 0937-941X Impact factor: 4.507
Fig. 1Flowchart diagram
Characteristics of the included studies
| Study | Study design | Patient selection | Number of participants | Number of patients with eGFR < 60/dialysis** | Age (me(di)an (± range) | % male | Me(di)an follow-up time in years (range) | Overall score quality assessment (…/9) | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accidental falls | Hip/femur +pelvis fractures | Vertebral fracture | Any type of fracture | |||||||||
| Alem, 2000 [ | RCS | US Renal Data System (USRDS) | ? | 326,464** | NR | 56% | ? (?–7) | 4 | X | |||
| Arneson, 2013 [ | RCS | Medicare, USA | 1,267,416* | 101,995** | ≥ 66 | 46%* | ? (?–1) | 7 | X | |||
| Atteritano, 2017 [ | CS | Population-based cohort, USA | 192 | 92** | 65.9* | 78%* | NA | 8 | X | |||
| Bowling, 2016 [ | PCS | Population-based cohort, USA (REGARDS) | 8744 | 1604 | ≥ 65 | 51% | 5.9 (?–9.9) | 7 | X | |||
| Chen, 2018 [ | PCS | Population-based cohort, The Netherlands (LASA) | 1477 | 560* | 75.8 ± 6.6 | 48% | ? (?–6) | 7/8 | X | X | X | |
| Coco, 2000 [ | RCS | Outpatient dialysis unit (monocenter) | NR | 1272 | 58 ± 0.4 | 49% | 3.2 (?–10) | 7 | X | |||
| Daya, 2016 [ | PCS | Population-based (ARIC), USA | 10,955 | 693 | 63.3* | 44%* | 13 (?–15) | 7 | X | |||
| Dooley, 2008 [ | RS | Multicenter Veteran clinic, USA | 33,091 | 13,632 | 67.5 (?) | 100% | 3 (?–7) | 8 | X | |||
| Dukas, 2005 [ | PCS | Multicenter study, Germany | 186 | NR | 75.0 ± 4.1 | 48%* | ? (?–0.7) | 6 | X | |||
| Dukas, 2005 [ | CS | Post hoc subanalysis of RCT | 5313 | NR | 74.0 (?) | 20% | NA | 6/5 | X | X | X | |
| Elliott, 2013 [ | PCS | Population-based cohort, Canada | 1,815,943 | 128,957 | ≥ 65 | 44% | 4.4 (?–6) | 5 | X | X | X | |
| Ensrud, 2007 [ | CC | Population-based cohort, USA (SOF) | 396 | 186 | ≥ 65 | 0% | 5.9 (?) | 6 | X | X | ||
| Ensrud, 2012 [ | CC | Multicenter cohort study, USA (WHI-OS) | 2190 | NR | 64.3* | 0% | 8.6 (?–12) | 8 | X | |||
| Ensrud, 2014 [ | CC | Population-based cohort, USA (MrOS) | 1602 | 388 | 73.8* | 100% | 7.9 (?–8) | 8 | X | |||
| Fried, 2007 [ | PCS | Population-based cohort, USA | 5888 | 1190* | 74.8* | 42%* | 7.1 (?) | 7 | X | |||
| Hall, 2015 [ | RCS | Multiple nursing homes, USA (RCT CONNECT for quality) | 510 | 179* | 77.2 ± 11.5 | 73% | 0.2 (?–0.5) | 7 | X | |||
| Hall, 2018 [ | PCS | Multicenter Veteran clinic, USA | 712,918 | 356,459 | 73.0* | 100% | 5.2 (?–10) | 6 | X | |||
| Hansen, 2016 [ | RCS | Danish population + all patients receiving dialysis in Denmark | 4,099,342 | 7566** | 46* | 49% | ? (?–2) | 6 | X | |||
| Iwagami, 2018 [ | RCS | Population-based cohort, England | 484,698 | 242,349 | 75.4 ± 9.7 | 39% | 4.2 (?–10) | 7 | X | |||
| Kaji, 2010 [ | CS | Outpatient clinic for metabolic bone disorders, Japan | 659 | 85 | 64.5 ± 8.2 | 0% | NA | 5 | X | |||
| Kim, 2016 [ | RCS | Multicenter cohort, USA (NIS) | 278,018 | 38,932 | NR | 31%* | ? (?–1) | 5 | X | |||
| Kinsella, 2010 [ | CS | Monocenter study, Ireland | 1702 | 347 | 61.7 ± 10.8 | 0% | 4 | X | ||||
| Kistler, 2018 [ | CS | Behavioral risk factor surveillance system (BRFSS), USA | 157,753 | 9116 | ≥ 65 | 44% | NA | 6 | X | |||
| Kurajoh, 2018 [ | CS | Multicenter study, Japan | 555 | 181 | 76.8* | 0% | NA | 6 | X | |||
| LaCroix, 2008 [ | CC | Multicenter cohort study, USA (WHI-OS) | 794 | 144 | 71 (?) | 0% | 7 (0.7–9.3) | 9 | X | |||
| Liao, 2016 [ | RCS | Population-based cohort, Taiwan (LHID2005) | 11,312 | 1427 | ≥ 40 | 68% | 2.6 (?–10) | 6 | X | |||
| Maravic, 2014 [ | RCS | French national database | 68,953 | 29,487** | 82.1* | 24%* | ? (?–1) | 5 | X | |||
| McCarthy, 2008 [ | PCS | Multicenter cohort + population-based cohort, USA | 427 | 85 | 68 ± 13.5 | 0% | 14 (?–25) | 7 | X | |||
| Mishima, 2015 [ | CS | Tertiary center, Japan | 173 | 68 | 62.3 ± 12.2 | 57% | NA | 4 | X | |||
| Naylor, 2014 [ | PCS | Population-based cohort, Canada | 679,114 | 107,841 | > 65 | 45%* | ? (?–3) | 7 | X | X | ||
| Naylor, 2015 [ | PCS | Population-based cohort, Canada (CaMos) | 2107 | 320 | 67.2* | 29% | 4.8 (?–5) | 4 | X | |||
| Nickolas, 2006 [ | CS | Population-based cohort, USA (NHANES III) | 6270 | 875 | 64.9* | 48%* | NA | 6 | X | |||
| Pérez-Sáez, 2015 [ | RCS | Population-based cohort, Spain (SIDIAPQ) | 873,073 | 32,934 | 67.6 | 47% | 3 (?–3) | 6 | X | |||
| Račić, 2015 [ | CS | Multiple HD centers, Bosnia and Herzegovina and Serbia + primary care center | 406 | 106** | 77.6* | 61% | NA | 4 | X | |||
| Rafiq, 2014 [ | RS | Multiple GP databases, UK (QICKD) | 135,433 | NR | 75.4 ± 7.6 | 44% | 2,5 (?–5) | 6 | X | |||
| Robertson, 2018 [ | RCS | Single health region Scotland | 39,630 | 19,882 | 63.3* | 41%* | ? (5.5–?) | 7 | X | |||
| Rothenbacher, 2014 [ | PCS | Population-based cohort, Ulm + Germany (ActiFE) | 1385 | 196 | 75.6 ± 6.5 | 57% | 1 (?–1) | 8 | X | |||
| Wakasugi, 2013 [ | RCS | All dialysis facilities in Japan | NR | 128,141 | NR | 62% | ? (?–1) | 4 | X | |||
| Yenchek, 2012 [ | PCS | Population-based cohort, USA (Health, aging, and body composition study) | 2754 | 587 | 73.6 ± 2.9 | 49%* | 11.3 (?) | 7 | X | |||
PCS prospective cohort study, CS cross-sectional study, RCS retrospective cohort study, CC case-control study, NR not reported, NA not applicable, ? not reported
*Calculated
**Only dialysis patients included
Fig. 2Quality assessment
Study results for the association between accidental falling and chronic kidney disease
| Accidental falls | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Degree of kidney impairment | Adjusted (+/−) | Reference group | |||||||
| eGFR method | < 15 | 15–29 | 30–44 | < 45 | 45–59 | < 60 | Other | |||
| Bowling, 2016 [ | CKD-EPI (creatinine) | HR 1.09 (0.86–1.37)‡ | HR 0.91 (0.76–1.09) | +a,b,c,d,e,f | ≥ 60 | |||||
| Chen, 2018 [ | MDRD (creatinine) | HR 0.999 (0.995–1.002) | +a,b,c,d | ≥ 74 | ||||||
| Dukas, 2005 [ | CG (creatinine) | OR 4.01 (1.48–10.89)‡ | +a,c,d,e | ≥ 65 | ||||||
| Dukas, 2005 [ | CG (creatinine) | OR 1.69 (1.50-1.91)‡ | +a,c,e | ≥ 65 | ||||||
| Hall, 2015 [ | MDRD (creatinine) | Rate ratio 1.06 (0.85–1.32) | Rate ratio 0.97 (0.76–1.23) | +a,f | ≥ 60 | |||||
| Kistler, 2018 [ | Self-report | OR 1.26 (1.13-1.47) | +a,d,f | Non-CKD | ||||||
| Naylor, 2014 [ | CKD-EPI (creatinine) | ♀ Risk ratio 3.45* | ♀Risk ratio 2.39* | ♀Risk ratio 2.00* | ♀Risk ratio 1.55* | − | ≥ 60 | |||
| Račić, 2015 [ | Hemodialysis | Risk ratio 4.7* | − | Non-CKD | ||||||
| Rafiq, 2014 [ | NHS codes | OR 0.9 (0.9–0.9) | OR 1.1 (1.1–1.2) | +a,b,d,e | ≥ 90 | |||||
| Rothenbacher, 2014 [ | CKD-EPI (cystatin C) | Risk ratio 1.03 (0.83-1.28)* | − | ≥ 60 | ||||||
CG Cockgroft-Gault formula, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MDRD Modification of Diet in Renal Disease, OR odds ratio, HR hazard ratio
*Calculated from available data
‡Dialysis patients and/or stage 5 excluded
Adjustment
aDemographics
bIntoxications (e.g., alcohol, smoking status)
cBMI, weight
dComorbidity
eUse of antihypertensive medication, psychoactive medication, antidepressants, sedatives, polypharmacy
fImpaired mobility
Fig. 3a–d Association between chronic kidney disease, accidental falls (a), hip fractures (b), vertebral fractures (c), and all fractures (d)
Study results for the association between hip/femur fractures and chronic kidney disease
| Hip/femur fractures | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Degree of kidney impairment | Adjusted (+/−) | Reference group | ||||||||
| eGFR method | < 15 | 15–29 | < 30 | 30–44 | < 45 | 45–59 | < 60 | Other | |||
| Alem, 2000 [ | Dialysis | ♂Rate ratio 4.44 (4.16–4.75) ♀Rate ratio 4.40 (4.16–4.64) | +a | General population | |||||||
| Arneson, 2013 [ | Hemodialysis | Rate ratio 4.0* | +a,d | Non-ESKD | |||||||
| Coco, 2000 [ | Dialysis | Rate ratio 17.4 (12.4–34.0) | − | General population | |||||||
| Dooley, 2008 [ | MDRD (creatinine) | ♂HR 3.65 (1.87–7.13)‡ | +a,b,c,f | General population | |||||||
| Dukas, 2005 [ | CG (creatinine) | OR 1.57 (1.18–2.09)‡ | +a,b,c,e,f | ≥ 65 | |||||||
| Elliott, 2013 [ | CKD-EPI (creatinine) | Rate ratio 3.46 (3.13–3.83)* | Rate ratio 2.53 (2.38–2.69)* | Rate ratio 1.62 (1.54–1.71)* | − | ≥ 60 | |||||
| Ensrud, 2007 [ | MDRD (creatinine) | ♀HR 1.58 (0.59–4.23) | ♀HR 1.49 (0.93–2.38) | +a,c,h | ≥ 60 | ||||||
| Ensrud, 2014 [ | CKD-EPI (creatinine) | ♂HR 0.92 (0.58–1.47) | +a,c,d,g,h | ≥ 60 | |||||||
| Fried, 2007 [ | MDRD (creatinine) | ♂ HR 0.97 (0.58–1.62) ♀ HR 1.38 (0.99-1.94) | +a,b,c,d | ≥ 60 | |||||||
| Iwagami, 2018 [ | CKD-EPI (creatinine) | HR 1.72 (1.59–1.85)‡ | HR 1.29 (1.24–1.36) | HR 1.04 (1.00–1.08) | HR 1.11 (1.07–1.15)‡ | +a,d,e | ≥ 60 | ||||
| Kim, 2016 [ | ICD | Rate ratio 3.30* | Rate ratio 1.53*‡ | +a,b,e,f,h | Normal kidney function | ||||||
| LaCroix, 2008 [ | Cystatin C^-1*76.7 | ♀OR 2.64 (1.41–4.97) | ♀OR 1.10 (0.71–1.73) | +a,b,c, | ≥ 90 | ||||||
| Maravic, 2014 [ | Dialysis | Rate ratio 4.1* | − | Non-dialysis | |||||||
| Nickolas, 2006 [ | MDRD (creatinine) | OR 2.32 (1.13–4.74)‡ | +a,b,c,d,g,h | ≥ 60 | |||||||
| Pérez-Sáez, 2015 [ | ICD | HR 1.16 (1.06–1.27) | +a,b,c,d,f | ≥ 60 | |||||||
| Robertson, 2018 [ | MDRD (creatinine) | Rate ratio 1.74 (1.30–2.33) | Rate ratio 1.70 (1.38–2.09) | Rate ratio 1.40 (1.16–1.70) | Rate ratio 1.49 (1.24–1.79) | +a,d | ≥ 60 | ||||
| Wakasugi, 2013 [ | Dialysis | ♂Rate ratio 6.2 (5.7–6.8) ♀Rate ratio 4.9 (4.6–5.3) | +a | General population | |||||||
CG Cockgroft-Gault formula, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MDRD Modification of Diet in Renal Disease, ESKD end-stage kidney disease, OR odds ratio, HR hazard ratio
*Calculated from available data
‡Dialysis patients and/or stage 5 excluded
Adjustment
aDemographics (e.g., age, sex, race)
bIntoxications (e.g., alcohol use, smoking status)
cBMI, weight
dComorbidity (e.g., diabetes, osteoporosis)
eAdjusted for antiosteoporotic treatment (e.g., bisphosphonates) or exclusion of patients with antiosteoporotic drug use
fUse of steroids, or exclusion of patients with steroid use
gLaboratory values (e.g., calcium, phosphorus, PTH, 25-OHD)
hBMD
Study results for the association between vertebral fractures and chronic kidney disease
| Vertebral fractures | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Degree of kidney impairment | Adjusted (+/−) | Reference group | ||||||
| eGFR method | < 15 | 15–29 | 30–44 | < 45 | 45–59 | < 60 | |||
| Atteritano, 2017 [ | Hemodialysis | OR 6.33 (2.92–13.73)* | +a | Normal kidney function | |||||
| Chen, 2018 [ | MDRD (creatinine) | OR 0.63 (0.53–1.24) | OR 0.86 (0.56–1.32) | +a,b,c,d | ≥ 60 | ||||
| Dukas, 2005 [ | CG (creatinine) | OR 1.31 (1.10–1.55)‡ | +a,b,c,e,f | ≥ 65 | |||||
| Elliott, 2013 [ | CKD-EPI (creatinine) | Rate ratio 1.61 (1.37–1.89)* | Rate ratio 1.67 (1.54–1.81)* | Rate ratio 1.35 (1.27–1.44)* | − | ≥ 60 | |||
| Ensrud, 2007 [ | MDRD (creatinine) | ♀ OR 0.73 (0.24–2.24) | ♀ OR 0.75 (0.45–1.23) | +a,c,h | ≥ 60 | ||||
| Kaji, 2010 [ | MDRD (creatinine) | ♀ OR 2.32 (1.45–3.71)* | −e,f | ≥ 60 | |||||
| Mishima, 2015 [ | Formula proposed by the Japanese Society of Nephrology | OR 2.48 (1.20–5.12)*‡ | −e,f | ≥ 60 | |||||
CG Cockgroft-Gault formula, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MDRD Modification of Diet in Renal Disease, OR odds ratio
*Calculated from available data
‡Dialysis patients and/or stage 5 excluded
Adjustment
aDemographics (e.g., age, sex, race)
bIntoxications (e.g., alcohol use, smoking status)
cBMI, weight
dComorbidity (e.g., diabetes, osteoporosis)
eAdjusted for anti-osteoporotic treatment (e.g., bisphosphonates) or exclusion of patients with antiosteoporotic drug use
fUse of steroids, or exclusion of patients with steroid use
gLaboratory values (e.g., calcium, phosphorus, PTH, 25-OHD)
hBMD
Study results for the association between any type of fracture and chronic kidney disease
| Any type of fracture | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Degree of kidney impairment | Adjusted (+/−) | Reference group | ||||||
| eGFR method | < 15 | 15–29 | 30–44 | 45–59 | < 60 | Other | |||
| Chen, 2018 [ | MDRD (creatinine) | HR 1.46 (1.12–1.91) | HR 1.28 (1.12–1.46) | +a,b,c,d | ≥ 60 | ||||
| Daya, 2016 [ | CKD-EPI (creatinine) | HR 0.89 (0.56–1.41) | +a,b,c,d,e,f | ≥ 90 | |||||
| Elliott, 2013 [ | CKD-EPI (creatinine) | Rate ratio 2.16 (2.00–2.34)* | Rate ratio 1.80 (1.72–1.88)* | Rate ratio 1.38 (1.33–1.42)* | − | ≥ 60 | |||
| Ensrud, 2012 [ | CKD-EPI (cystatin C) | ♀HR 2.46 (1.16–5.21) | ♀HR 1.16 (0.85–1.58) | +a,e | ≥ 90 | ||||
| Hall, 2018 [ | MDRD | ♂HR 1.91 (1.45–2.50) | ♂HR 1.32 (1.16–1.49) | +a,b,c,d,e | ≥ 60 | ||||
| Hansen, 2016 [ | Dialysis | HR 1.85 (1.75–1.95) | +a,d,e | General population | |||||
| Kinsella, 2010 [ | MDRD (creatinine) | ♀OR 1.37 (1.0–1.89) | ♀OR 1.20 (0.93–1.55) | +a,e,f | 75–89 | ||||
| Kurajoh, 2018 [ | Japanese formula for eGFRcr | OR 0.96 (0.85–1.01) | +a,b,c,d | NA | |||||
| Liao, 2016 [ | ? | HR 1.10 (0.95–1.27) | +a,d,f | No CKD | |||||
| McCarthy, 2008 [ | MDRD | HR 0.92 (0.84–1.01) | +a,c | NA | |||||
| Naylor, 2014 [ | CKD-EPI | ♂ Rate ratio 4.3 (3.70–5.00) ♀Rate ratio 3.1 (2.80–3.50) | ♂Rate ratio 2.7 (2.20–3.30) ♀Rate ratio 2.1 (1.90–2.30) | ♂Rate ratio 1.8 (1.60–2.00) ♀Rate ratio 1.6 (1.50–1.70) | ♂Rate ratio 1.3 (1.20–1.40) ♀Rate ratio 1.40 (1.30–1.50) | − | ≥ 60 | ||
| Naylor, 2015 [ | CKD-EPI (creatinine) | Risk ratio 1.86 (1.07–3.24)* | − | ≥ 60 | |||||
| Yenchek, 2012 [ | MDRD (creatinine) | Risk Ratio 1.26 (1.02–1.56)* | − | ≥ 60 | |||||
CG Cockgroft-Gault formula, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MDRD Modification of Diet in Renal Disease, CKD chronic kidney disease
*Calculated from available data
‡Dialysis patients and/or stage 5 excluded
Adjustment
aDemographics (e.g., age, sex, race)
bIntoxications (e.g., alcohol use, smoking status)
cBMI, weight
dComorbidity (e.g., diabetes, osteoporosis)
eAdjusted for antiosteoporotic treatment (e.g., bisphosphonates) or exclusion of patients with antiosteoporotic drug use
fUse of steroids, or exclusion of patients with steroid use
gLaboratory values (e.g., calcium, phosphorus, PTH, 25-OHD)
hBMD
Fig. 4a Associations of chronic kidney disease with incidence of hip fractures. b Associations of chronic kidney disease with any type of fracture